首页> 美国政府科技报告 >Application of Food and Drug Administration (FDA) Rules to Department of Defense Force Health Protection Programs.

【24h】

Application of Food and Drug Administration (FDA) Rules to Department of Defense Force Health Protection Programs.

机译：食品药品管理局（FDa）规则在国防部健康保护计划中的应用。

获取原文

页面导航

摘要
著录项
相似文献
相关主题

摘要

This Instruction: (1.1) Reissues Reference (a) as a DoD Instruction in accordance with the guidance in Reference (b) and the authority in Reference (c); (1.2) Updates policy and assigns responsibility for compliance with Reference (d); sections 1107 and 1 ...

著录项

作者

展开▼
作者单位

展开▼
年度 2008
页码 1-12
总页数 12
原文格式 PDF
正文语种 eng
中图分类工业技术;
关键词
Compliance; Department of defense; FDA(Food and drug administration); Food and drug administration(FDA); Health; Instructions; Medical products; Regulations;

机译：合规;国防部; FDa（食品和药品管理）;食品和药品管理局（FDa）;健康;说明;医疗产品;法规;

相似文献

外文文献
中文文献
专利

1. American Epilepsy Society (AES): Written Comments to Norman E. "Ned" Sharpless, MD, Acting Commissioner of Food and Drugs, US Food and Drug Administration (FDA), Department of Health and Human Services (HHS) on Docket ID# FDA-2019-N-1482, Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing; Request for Comments: Submitted on: July 16, 2019 [J] . Welty Timothy E., Chapman Kevin E., Faught R. Edward Jr., Nature reviews Cancer . 2019,第6期

机译：美国癫痫社会（AES）：对Norman E.“Ned”的书面评论是“NED”Sharpless，MD，食品和药物代理人专员，美国食品和药物管理局（FDA），卫生和人类服务部（HHS）在Docket ID＃FDA -2019-n-1482，科学数据和有关包含大麻或大麻衍生化合物的产品的信息; 公开听证会; 申请评论：提交：2019年7月16日
2. Juries Trump FDA in Writing Drug Labels; FDA Grants Clinical Trial Permission for Human Embryonic Stem Cells; Alerts Issued for Two Biotechnology Products; Japanese Rheumatoid Arthritis Drug Approved in Europe; FDA Criticizes Humira Ad; Amgen's BLA for Bone Drug Accepted; Rules for Claiming Health Benefits from Food and Supplements [J] . Biotechnology Law Report . 2009,第2期

机译：陪审团特朗普FDA撰写药品标签； FDA授予人类胚胎干细胞临床试验许可；两种生物技术产品发出警报；日本在欧洲批准了类风湿关节炎药物； FDA批评Humira广告；接受了安进公司的骨药物BLA；从食品和补品中获取健康益处的规定
3. Current FDA-Related Drug Information New Drugs Approved by the FDA New Dosage Forms and Indications Approved by the FDA Agents Pending FDA Approval New Drug/Biologies License Applications Filed by Manufacturer Supplemental Applications Filed by Manufacturer Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety [J] . Danial E. Baker Hospital pharmacy. . 2010,第6期

机译：当前与FDA有关的药物信息由FDA批准的新药物，由FDA代理商批准的新剂型和适应症，待FDA批准的制造商提出的新药/生物许可申请，制造商提出的补充申请，重要的标签变更或与“亲爱的健康专业人员”的信件安全
4. CARDIOVASCULAR MEDICAL DEVICES: REGULATORY SCIENCE RESEARCH OVERVIEW IN THE OFFICE OF SCIENCE AND ENGINEERING LABORATORIES (OSEL) AT THE FOOD AND DRUG ADMINISTRATION (FDA) [C] . Kenneth Aycock, Ksenia Blinova, Maura Casciola, Design of Medical Devices Conference . 2021

机译：心血管医疗器械：监管科学研究概述在食品和药物管理局（FDA）的科学与工程实验室（OSEL）办公室
5. Role of Patient Advocacy Stakeholders in Science-Based Regulatory Policy at the U.S. Food and Drug Administration (FDA) [D] . Kuehn, Carrie Melissa. 2017

机译：患者倡导利益相关者在美国食品和药物管理局（FDA）的科学研究政策中的作用
6. American Epilepsy Society (AES): Written Comments to Norman E. NedSharpless MD Acting Commissioner of Food and Drugs U.S. Food and DrugAdministration (FDA) Department of Health and Human Services(HHS) [O] . Timothy E. Welty, Kevin E. Chapman, R. Edward Faught, 2019

机译：美国癫痫病学会（AES）：对Norman E. Ned的书面评论医学博士Sharpless美国食品和药物代理专员卫生与公共服务部行政管理（FDA）（HHS）
7. American Epilepsy Society (AES): Written Comments to Norman E. “Ned” Sharpless, MD, Acting Commissioner of Food and Drugs, U.S. Food and Drug Administration (FDA), Department of Health and Human Services (HHS) [O] . Timothy E. Welty, Kevin E. Chapman, R. Edward Faught, 2019

机译：美国癫痫社会（AES）：对Norman E.“Ned”的书面评论，美国食品和药物毒品和毒品代理专员，美国食品和药物管理局（FDA），卫生和人类服务部（HHS）

Application of Food and Drug Administration (FDA) Rules to Department of Defense Force Health Protection Programs.

摘要

著录项

相似文献

相关主题

期刊订阅